Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by SrPlataon Oct 14, 2021 10:07pm
167 Views
Post# 34007766

Way, Way too Early for a Buyout, But!!!!

Way, Way too Early for a Buyout, But!!!!Think about this, If big Pharma is looking to buyout Arch. It would have to be an extremley generous offer to current market price 5X, 6x,7x, 10x?????Who knows. But Arch insiders won't sell us out cheaply like some management would, IE If they own less than 10% and they are offered Golden Parachutes with generous  severance packages they will sell out shareholders for their own benefit. Arch Management and insiders own roughly 59% Plus another 6% Friends and Family. In addition Mgt knows what they have on their hands and how valuable the platform technology is. Arch developed this Drug Platform over 10 years and own it outright unlike other Bio Tech companies that licence the formula from Universities or others. So no Royalties over hanging them. Basically Arch is in the drivers seat and will control their(our) destiny.
<< Previous
Bullboard Posts
Next >>